Page last updated: 2024-09-05

sb 203580 and Testicular Neoplasms

sb 203580 has been researched along with Testicular Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Iordanov, MS; Kapoor, M; Keller, D; Li, X; Lozano, G; Lu, H; Magun, B; Taya, Y; Zeng, X	1

Other Studies

1 other study(ies) available for sb 203580 and Testicular Neoplasms

Article	Year
The p38MAPK inhibitor SB203580 alleviates ultraviolet-induced phosphorylation at serine 389 but not serine 15 and activation of p53. Biochemical and biophysical research communications, 1999, Aug-02, Volume: 261, Issue:2 Topics: Animals; Apoptosis; Calcium-Calmodulin-Dependent Protein Kinases; Enzyme Inhibitors; Humans; Imidazoles; In Vitro Techniques; Male; Mice; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Serine; Testicular Neoplasms; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Ultraviolet Rays	1999

Article

Year

The p38MAPK inhibitor SB203580 alleviates ultraviolet-induced phosphorylation at serine 389 but not serine 15 and activation of p53.

Biochemical and biophysical research communications, 1999, Aug-02, Volume: 261, Issue:2

Topics: Animals; Apoptosis; Calcium-Calmodulin-Dependent Protein Kinases; Enzyme Inhibitors; Humans; Imidazoles; In Vitro Techniques; Male; Mice; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Serine; Testicular Neoplasms; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Ultraviolet Rays

1999